Sex arbic

χ or Fisher’s exact tests were used to evaluate categorical variables, as appropriate.For the primary end points for each sex group, we examined differences between the treatment groups using the log-rank test stratified by age and risk factors.

sex arbic-6

However, in this guideline, there is no mention of the selection of antihypertensive drugs based on sex, with the exception of pregnancy-related situations.However, only a few cardiovascular trials have provided sex-specific data, and sex differences remain poorly understood.The baseline characteristics of the randomized patients have been described in the report of the OSCAR study’s main per day olmesartan (ARB plus CCB combination therapy).If further additional antihypertensive treatment was required to achieve the target BP, other antihypertensive drugs could be added, excluding angiotensin-converting enzyme inhibitors, ARBs and CCBs. The primary end point of the main OSCAR study was the time to the first event.The primary end point events were a composite of fatal and non-fatal cardiovascular events, including the following: cerebrovascular disease (cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage, unspecified stroke and transient ischemic attack); coronary artery disease (sudden death, myocardial infarction, angina pectoris and asymptomatic cardiac ischemia); heart failure; other arteriosclerotic disease (aortic aneurysm, aortic dissection and atherosclerotic disease); diabetic complications (diabetic neuropathy, retinopathy and nephropathy); deterioration of renal function (doubling of serum creatinine, end-stage renal disease as defined by initiation of hemodialysis of renal transplantation); and non-cardiovascular death.

The secondary end points were the incidence of each cardiovascular event, change in BP during the follow-up period and serious adverse events other than the primary end points.The mean differences in systolic and diastolic BPs were 2.6Serial changes in systolic and diastolic blood pressures (SBP and DBP) in male and female patients and in the high-dose angiotensin II receptor blocker (ARB) and ARB plus calcium channel blocker (CCB) groups.Full figure and legend (110Similarly, for the female patients, both the systolic and diastolic BPs were higher in the high-dose ARB group than in the ARB plus CCB group, and the mean difference in systolic BP in the two treatment groups was 2.80.15).The primary end point was a composite of cardiovascular events and non-cardiovascular death.The baseline characteristics between the two treatment groups in each sex were similar, except for some variables.A repeated measures of analysis of variance was used to compare BP during the follow-up period between the groups, and the least square method was used to estimate the mean difference in BP between the treatment groups.